Intensificação da coloração da epiderme de pêssegos cv. Eldorado, em função do uso de cobertura plástica no solo.

bitstream/item/31610/1/comunicado83.pd

Resultados do ensaio nacional de sorgo granífero - 1975/76 e 1976/77.

Sorgo granifero; Variedade; Sorghum bicolor; Varieties.bitstream/item/43238/1/Bol-tec-1.pd

An overview of heavy oil properties and its recovery and transportation methods

Unconventional oils - mainly heavy oils, extra heavy oils and bitumens - represent a significant share of the total oil world reserves. Oil companies have expressed interest in unconventional oil as alternative resources for the energy supply. These resources are composed usually of viscous oils and, for this reason, their use requires additional efforts to guarantee the viability of the oil recovery from the reservoir and its subsequent transportation to production wells and to ports and refineries. This review describes the main properties of high-viscosity crude oils, as well as compares traditional and emergent methods for their recovery and transportation. The main characteristics of viscous oils are discussed to highlight the oil properties that affect their flowability in the processes of recovery and pipeline transportation. Chemical composition is the starting point for the oil characterization and it has major impact on other properties, including key properties for their dynamics, such as density and viscosity. Next, enhanced oil recovery (EOR) methods are presented, followed by a discussion about pipeline and transportation methods. In addition, the main challenges to achieve viable recovery and transportation of unconventional oils are compared for the different alternatives proposed. The work is especially focused on the heavy oils, while other hydrocarbon solid sources, such as oil sands and shale oil, are outside of the scope of this review31357159

PP271—Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade

n/

Cross-country comparison of monetary values from SHARELIFE

The SHARELIFE survey contains a set of questions aimed to collect monetary information, such as incomes from work, pension benefits, and house values. Given the retrospective structure of the questionnaire, these amounts refer to different points in time and different currencies. Heterogeneity in time and currencies raises comparability problems: the purpose of this paper is to describe a procedure aimed to generate comparable amounts for the monetary variables in SHARELIFE

High-resolution abundance analysis of red giants in the globular cluster NGC 6522

The [Sr/Ba] and [Y/Ba] scatter observed in some galactic halo stars that are very metal-poor stars and in a few individual stars of the oldest known Milky Way globular cluster NGC 6522,have been interpreted as evidence of early enrichment by massive fast-rotating stars (spinstars). Because NGC 6522 is a bulge globular cluster, the suggestion was that not only the very-metal poor halo stars, but also bulge stars at [Fe/H]~-1 could be used as probes of the stellar nucleosynthesis signatures from the earlier generations of massive stars, but at much higher metallicity. For the bulge the suggestions were based on early spectra available for stars in NGC 6522, with a medium resolution of R~22,000 and a moderate signal-to-noise ratio. The main purpose of this study is to re-analyse the NGC 6522 stars previously reported using new high-resolution (R~45,000) and high signal-to-noise spectra (S/N>100). We aim at re-deriving their stellar parameters and elemental ratios, in particular the abundances of the neutron-capture s-process-dominated elements such as Sr, Y, Zr, La, and Ba, and of the r-element Eu. High-resolution spectra of four giants belonging to the bulge globular cluster NGC 6522 were obtained at the 8m VLT UT2-Kueyen telescope with the UVES spectrograph in FLAMES-UVESconfiguration. The spectroscopic parameters were derived based on the excitation and ionization equilibrium of \ion{Fe}{I} and \ion{Fe}{II}. Our analysis confirms a metallicity [Fe/H] = -0.95+-0.15 for NGC 6522, and the overabundance of the studied stars in Eu (with +~0.2 < [Eu/Fe] < +~0.4) and alpha-elements O and Mg. The neutron-capture s-element-dominated Sr, Y, Zr, Ba, La now show less pronounced variations from star to star. Enhancements are in the range 0.0 < [Sr/Fe] < +0.4, +0.23 < [Y/Fe] < +0.43, 0.0 < [Zr/Fe] < +0.4, 0.0 < [La/Fe] < +0.35,and 0.05 < [Ba/Fe] < +0.55.Comment: date of acceptation: 31/07/2014, in press, 24 pages, 19 figures,Astronomy & Astrophysics, 201

PP272—Migraine and parthenolide inhibition of transient receptor potential ankyrin 1

2013 e103 emerged as a major complication of bortezomib therapy, which usually appears in the first courses of therapy with a number of sensory and painful symptoms, including reduced threshold to mechanical and cold stimuli. No satisfactory explanation or effective treatment exists for bortezomib-evoked CIPN. Patients (or Materials) and Methods: In this study, we evaluated whether TRPA1 acted as a critical mediator of CIPN by bortezomib or oxaliplatin in a mouse model system. Results: Our data demonstrated that CIPN hypersensitivity phenotype that was stably established by bortezomib could be transiently reverted by systemic or local treatment with the TRPA1 antagonist HC-030031. A similar effect was produced by the oxidative stress scavenger α -lipoic acid. Notably, the CIPN phenotype was abolished completely in mice that were genetically deficient in TRPA1, highlighting its essential role. Administration of bortezomib or oxaliplatin, which also elicits TRPA1-dependent hypersensitivity, produced a rapid, transient increase in plasma of carboxy-methyllysine, a byproduct of oxidative stress. Short-term systemic treatment with either HC-030031 or α -lipoic acid could completely prevent hypersensitivity if administered before the cytotoxic drug. Conclusion: Our findings highlight a key role for early activation/ sensitization of TRPA1 by oxidative stress by-products in producing CIPN. Furthermore, they suggest prevention strategies for CIPN in patients through the use of early, short-term treatments with TRPA1 antagonists. Disclosure of Interest: None declared